SCHEMBL2654072

SCHEMBL2654072

CS(=O)(=O)Cc1ccc(-c2cc(C#N)cc3ncn(-c4ccccc4)c23)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.40
ALDH1A1 P00352 1/20 0.40
FGFR1 P11362 6/20 0.38
MET P08581 1/20 0.34
AKT1 P31749 2/20 0.34
SRC P12931 2/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.33
CSF1R P07333 1/20 0.33
MMP13 P45452 1/20 0.33
MAP4K1 Q92918 1/20 0.33
PTGS1 P23219 1/20 0.33
PTGS2 P35354 1/20 0.33
PIK3CD O00329 1/20 0.33
PDPK1 O15530 1/20 0.33
PIK3CA P42336 1/20 0.33
PIK3CB P42338 1/20 0.33
PIK3CG P48736 1/20 0.33
ACVR1 Q04771 1/20 0.33
GAK O14976 1/20 0.33
KDR P35968 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2655351 0.90 FGFR1 (0.39) MAPTALDH1A1FGFR1METPTGDR2
SCHEMBL2654098 0.85 FGFR1 (0.42) FGFR1METAKT1SRCPTGDR2
SCHEMBL2654894 0.83 FGFR1 (0.44) MAPTALDH1A1FGFR1METSRC
SCHEMBL2654636 0.82 FGFR1 (0.41) FGFR1METAKT1SRCPIK3CD
SCHEMBL2654102 0.80 FGFR1 (0.47) FGFR1METSRC
SCHEMBL2654014 0.80 KDR (0.54) MAPTALDH1A1FGFR1SRCGAK
SCHEMBL2654084 0.79 CYP19A1 (0.43) MAPTALDH1A1FGFR1METSRC
SCHEMBL2656918 0.78 FGFR1 (0.42) FGFR1METSRCPTGDR2
SCHEMBL2655939 0.78 ALDH1A1 (0.51) MAPTALDH1A1FGFR1KDR
Trifluoroacetic Acid SCHEMBL2660115 0.78 SLC2A1 (0.36) FGFR1PTGDR2ACVR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7700638-B2 1,5,7-trisubstituted benzimidazole derivatives and their use for modulating the GABAA receptor complex N. V. ORGANON (NL) 2010-04-20 US disclosed
US-20070021482-A1 1,5,7-Trisubstituted benzimidazole derivatives and their use for modulating the gabaa receptor complex N.V. ORGANON (NL) 2007-01-25 US disclosed
EP-1678144-A1 1,5,7-TRISUBSTITUTED BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA-a RECEPTOR COMPLEX Akzo Nobel N.V. (NL) 2006-07-12 EP disclosed
WO-2005040131-A1 1,5,7-TRISUBSTITUTED BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX AKZO NOBEL N.V. (NL) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021482-A1 1,5,7-Trisubstituted benzimidazole derivatives and their use for modulating the gabaa receptor complex GABRB1, GABRA5, GABRB2 MAPT 1065/4885ALDH1A1 541/4885FGFR1 2259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.